

AMENDMENTS THE CLAIMS

Claims 1-14 (Canceled).

Claim 15 (Currently Amended): A pharmaceutical composition having antithrombotic efficacy comprising a pharmaceutically acceptable carrier and a monoclonal antibody having the following properties:

- (a) the monoclonal antibody binds to human von Willebrand Factor; and
- (b) the monoclonal antibody inhibits binding between a monoclonal antibody produced by hybridoma and human von Willebrand Factor, ~~when the monoclonal antibody is allowed to co-exist with a monoclonal antibody produced by a~~ wherein the hybridoma ~~which is selected from the group consisting of FERM BP-5248 (AJvW-2), and FERM BP-5250 (AJvW-4), or~~ and a variant of any of them said hybridoma.

Claim 16 (Currently Amended): The ~~monoclonal antibody~~ pharmaceutical composition according to Claim 15, ~~which~~ wherein said monoclonal antibody is produced by a hybridoma formed by fusion between mouse myeloma cells and spleen cells of a mouse immunized with human von Willebrand factor.

Claim 17 (Currently Amended): The ~~monoclonal antibody~~ pharmaceutical composition according to Claim 15, wherein the hybridoma is FERM BP-5248 (AJvW-2).

Claim 18 (Currently Amended): The ~~monoclonal antibody~~ pharmaceutical composition according to Claim 15, wherein the hybridoma is a variant of FERM BP-5248 (AJvW-2).

Claim 19 (Currently Amended): The ~~monoclonal antibody~~ pharmaceutical composition according to Claim 15, wherein the hybridoma is FERM BP-5250 (AJvW-4).

Claim 20 (Currently Amended): The ~~monoclonal antibody~~ pharmaceutical composition according to Claim 15, wherein the hybridoma is a variant of FERM BP-5250 (AJvW-4).

Claim 21 (Currently Amended): A ~~The~~ pharmaceutical composition having antithrombotic efficacy comprising the monoclonal antibody defined in according to Claim 15, wherein said and a pharmaceutically acceptable carrier is one or more excipients selected from the group consisting of lactose, potato starch, calcium carbonate, sodium alginate, water, saline, Ringer's solution, and a dispersing agent.

SUPPORT FOR THE AMENDMENTS

Claims 15-21 have been amended.

The specification has been amended to include a brief summary of the invention, to update the status of US 09/299,016, and to correct minor typographical errors.

The amendments to Claims 15-20 are supported by previously pending Claims 15-21 and the specification at page 17, line 21 to page 18, line 22 and page 19, line 7 to page 27, line 19. The amendment of Claim 21 is supported by page 27, lines 5-19.

No new matter was added to the application by virtue of the present amendment.